Cipla, Alkem Laboratories in final lap to buy SMT

Promoters of SMT—the Kotadia family— plan to keep a minority stake after the transaction that would see other shareholders also divest their holdings. “They could retain about 15-20% stake post the deal,” said one of the persons cited above. Morgan Stanley PE Asia and Samara Capital collectively own 49% of SMT, while Kotak Pre-IPO Opportunities Fund has a 6% stake. The Kotadias own the remaining 45%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O743IdY
via IFTTT